Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Rheumatoid Arthritis

  Free Subscription


Articles published in Arthritis Res Ther

Retrieve available abstracts of 196 articles:
HTML format
Text format



Single Articles


    September 2017
  1. TAKEUCHI T, Miyasaka N, Inui T, Yano T, et al
    High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the R
    Arthritis Res Ther. 2017;19:194.
    PubMed     Text format     Abstract available


  2. ZIEGELASCH M, Forslind K, Skogh T, Riklund K, et al
    Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year.
    Arthritis Res Ther. 2017;19:195.
    PubMed     Text format     Abstract available


    August 2017
  3. SHAH NR, Noll BD, Stevens CB, Brennan MT, et al
    Biosemantics guided gene expression profiling of Sjogren's syndrome: a comparative analysis with systemic lupus erythematosus and rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:192.
    PubMed     Text format     Abstract available


  4. VAN DELFT MAM, Verheul MK, Burgers LE, Derksen VFAM, et al
    The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients.
    Arthritis Res Ther. 2017;19:190.
    PubMed     Text format     Abstract available


  5. NAKAGAWA J, Koyama Y, Kawakami A, Ueki Y, et al
    A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
    Arthritis Res Ther. 2017;19:185.
    PubMed     Text format     Abstract available


  6. LUNDSTROM SL, Hensvold AH, Rutishauser D, Klareskog L, et al
    IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:182.
    PubMed     Text format     Abstract available


    July 2017
  7. JAMSHIDI A, Gharibdoost F, Vojdanian M, Soroosh SG, et al
    A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA(R)) to the reference product (Humira(R)) in patients with active rheumat
    Arthritis Res Ther. 2017;19:168.
    PubMed     Text format     Abstract available


  8. TEITSMA XM, Jacobs JWG, Mokry M, Borm MEA, et al
    Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.
    Arthritis Res Ther. 2017;19:170.
    PubMed     Text format     Abstract available


  9. MACLAUCHLAN S, Zuriaga MA, Fuster JJ, Cuda CM, et al
    Genetic deficiency of Wnt5a diminishes disease severity in a murine model of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:166.
    PubMed     Text format     Abstract available


  10. BONDT A, Nicolardi S, Jansen BC, Kuijper TM, et al
    IgA N- and O-glycosylation profiling reveals no association with the pregnancy-related improvement in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:160.
    PubMed     Text format     Abstract available


  11. JIN Y, Desai RJ, Liu J, Choi NK, et al
    Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:159.
    PubMed     Text format     Abstract available


  12. SCHOELS M, Alasti F, Smolen JS, Aletaha D, et al
    Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
    Arthritis Res Ther. 2017;19:155.
    PubMed     Text format     Abstract available


  13. CASTANEDA S, Llorente I, Garcia-Vicuna R, Gonzalez-Alvaro I, et al
    Anti-citrullinated protein antibodies and bone loss in patients with early arthritis: comment on the article "Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untr
    Arthritis Res Ther. 2017;19:152.
    PubMed     Text format    


  14. OH BR, Suh DH, Bae D, Ha N, et al
    Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.
    Arthritis Res Ther. 2017;19:154.
    PubMed     Text format     Abstract available


    June 2017
  15. KOKKONEN H, Stenlund H, Rantapaa-Dahlqvist S
    Cardiovascular risk factors predate the onset of symptoms of rheumatoid arthritis: a nested case-control study.
    Arthritis Res Ther. 2017;19:148.
    PubMed     Text format     Abstract available


  16. CABRERA-VILLALBA S, Gomara MJ, Canete JD, Ramirez J, et al
    Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:141.
    PubMed     Text format     Abstract available


  17. SOLOMON DH, Shadick NA, Weinblatt ME, Zak A, et al
    Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement.
    Arthritis Res Ther. 2017;19:130.
    PubMed     Text format     Abstract available


    May 2017
  18. TEJERA-SEGURA B, Macia-Diaz M, Machado JD, de Vera-Gonzalez A, et al
    HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis.
    Arthritis Res Ther. 2017;19:113.
    PubMed     Text format     Abstract available


  19. BOETERS DM, Mangnus L, Ajeganova S, Lindqvist E, et al
    The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical.
    Arthritis Res Ther. 2017;19:115.
    PubMed     Text format     Abstract available


  20. YOO J, Lee SK, Lim M, Sheen D, et al
    Exosomal amyloid A and lymphatic vessel endothelial hyaluronic acid receptor-1 proteins are associated with disease activity in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:119.
    PubMed     Text format     Abstract available


  21. BUSTAMANTE MF, Garcia-Carbonell R, Whisenant KD, Guma M, et al
    Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:110.
    PubMed     Text format     Abstract available


  22. SHODA H, Nagafuchi Y, Tsuchida Y, Sakurai K, et al
    Increased serum concentrations of IL-1 beta, IL-21 and Th17 cells in overweight patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:111.
    PubMed     Text format     Abstract available


  23. KAWASHIRI SY, Fujikawa K, Nishino A, Okada A, et al
    Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are
    Arthritis Res Ther. 2017;19:108.
    PubMed     Text format     Abstract available


  24. GOIN DE, Smed MK, Pachter L, Purdom E, et al
    Pregnancy-induced gene expression changes in vivo among women with rheumatoid arthritis: a pilot study.
    Arthritis Res Ther. 2017;19:104.
    PubMed     Text format     Abstract available


  25. DERAMBURE C, Dzangue-Tchoupou G, Berard C, Vergne N, et al
    Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:109.
    PubMed     Text format     Abstract available


  26. PENATTI A, Facciotti F, De Matteis R, Larghi P, et al
    Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:103.
    PubMed     Text format     Abstract available


  27. THIEL J, Rizzi M, Engesser M, Dufner AK, et al
    B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
    Arthritis Res Ther. 2017;19:101.
    PubMed     Text format     Abstract available


  28. NAKACHI S, Sumitomo S, Tsuchida Y, Tsuchiya H, et al
    Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:97.
    PubMed     Text format     Abstract available


  29. GRABNER M, Boytsov NN, Huang Q, Zhang X, et al
    Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis.
    Arthritis Res Ther. 2017;19:92.
    PubMed     Text format     Abstract available


  30. STANDISH KA, Huang CC, Curran ME, Schork NJ, et al
    Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies.
    Arthritis Res Ther. 2017;19:90.
    PubMed     Text format     Abstract available


  31. SAUER BC, Teng CC, Accortt NA, Burningham Z, et al
    Models solely using claims-based administrative data are poor predictors of rheumatoid arthritis disease activity.
    Arthritis Res Ther. 2017;19:86.
    PubMed     Text format     Abstract available


  32. RYKOVA E, Sizikov A, Roggenbuck D, Antonenko O, et al
    Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers.
    Arthritis Res Ther. 2017;19:85.
    PubMed     Text format     Abstract available


    April 2017
  33. REED GW, Collier DH, Koenig AS, Saunders KC, et al
    Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:81.
    PubMed     Text format     Abstract available


  34. ISSA SF, Duer A, Ostergaard M, Horslev-Petersen K, et al
    Increased galectin-3 may serve as a serologic signature of pre-rheumatoid arthritis while markers of synovitis and cartilage do not differ between early undifferentiated arthritis subsets.
    Arthritis Res Ther. 2017;19:80.
    PubMed     Text format     Abstract available


  35. KUIJPER TM, Folmer R, Stolk EA, Hazes JMW, et al
    Doctors' preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment.
    Arthritis Res Ther. 2017;19:78.
    PubMed     Text format     Abstract available


  36. ANDRES CEREZO L, Sumova B, Prajzlerova K, Veigl D, et al
    Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:79.
    PubMed     Text format     Abstract available


  37. KUULIALA K, Kuuliala A, Koivuniemi R, Kautiainen H, et al
    Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:75.
    PubMed     Text format     Abstract available


  38. TAKAHASHI S, Saegusa J, Sendo S, Okano T, et al
    Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:76.
    PubMed     Text format     Abstract available


  39. KILTZ U, von Zabern C, Baraliakos X, Heldmann F, et al
    Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis - the TryCort study.
    Arthritis Res Ther. 2017;19:73.
    PubMed     Text format     Abstract available


    March 2017
  40. MENG W, Zhu Z, Jiang X, Too CL, et al
    DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:71.
    PubMed     Text format     Abstract available


  41. ALBRECHT K, Zink A
    Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies.
    Arthritis Res Ther. 2017;19:68.
    PubMed     Text format     Abstract available


  42. VAN DEN BRANDT S, Zbinden A, Baeten D, Villiger PM, et al
    Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
    Arthritis Res Ther. 2017;19:64.
    PubMed     Text format     Abstract available


  43. TANAKA Y, Yamanaka H, Ishiguro N, Miyasaka N, et al
    Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.
    Arthritis Res Ther. 2017;19:56.
    PubMed     Text format     Abstract available


  44. HUIZINGA TW, Batalov A, Stoilov R, Lloyd E, et al
    Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:53.
    PubMed     Text format     Abstract available


    February 2017
  45. HILLEN J, Geyer C, Heitzmann M, Beckmann D, et al
    Structural cartilage damage attracts circulating rheumatoid arthritis synovial fibroblasts into affected joints.
    Arthritis Res Ther. 2017;19:40.
    PubMed     Text format     Abstract available


  46. DIMITROULAS T, Hodson J, Sandoo A, Smith J, et al
    Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation.
    Arthritis Res Ther. 2017;19:32.
    PubMed     Text format     Abstract available


  47. SALOMON S, Guignant C, Morel P, Flahaut G, et al
    Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:33.
    PubMed     Text format     Abstract available


  48. TSUKAMOTO M, Seta N, Yoshimoto K, Suzuki K, et al
    CD14brightCD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:28.
    PubMed     Text format     Abstract available


  49. PANDYA JM, Lundell AC, Andersson K, Nordstrom I, et al
    Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker.
    Arthritis Res Ther. 2017;19:20.
    PubMed     Text format     Abstract available


  50. SHCHETYNSKY K, Diaz-Gallo LM, Folkersen L, Hensvold AH, et al
    Discovery of new candidate genes for rheumatoid arthritis through integration of genetic association data with expression pathway analysis.
    Arthritis Res Ther. 2017;19:19.
    PubMed     Text format     Abstract available


    January 2017
  51. IZUMI Y, Akazawa M, Akeda Y, Tohma S, et al
    The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial.
    Arthritis Res Ther. 2017;19:15.
    PubMed     Text format     Abstract available


  52. SELLAM J, Riviere E, Courties A, Rouzaire PO, et al
    Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:11.
    PubMed     Text format    


  53. HUFFMAN KM, Jessee R, Andonian B, Davis BN, et al
    Molecular alterations in skeletal muscle in rheumatoid arthritis are related to disease activity, physical inactivity, and disability.
    Arthritis Res Ther. 2017;19:12.
    PubMed     Text format     Abstract available


  54. XIE J, Wang H
    Semaphorin 7A as a potential immune regulator and promising therapeutic target in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:10.
    PubMed     Text format     Abstract available


  55. ZAVADA J, Hanova P, Hurnakova J, Szczukova L, et al
    The relationship between synovitis quantified by an ultrasound 7-joint inflammation score and physical disability in rheumatoid arthritis - a cohort study.
    Arthritis Res Ther. 2017;19:5.
    PubMed     Text format     Abstract available


  56. NORDAL HH, Brokstad KA, Solheim M, Halse AK, et al
    Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:3.
    PubMed     Text format     Abstract available


  57. HUGO M, Mehsen-Cetre N, Pierreisnard A, Pupier E, et al
    High body mass index in rheumatoid arthritis: why we should promote physical activity.
    Arthritis Res Ther. 2017;19:2.
    PubMed     Text format    


    December 2016
  58. HULL DN, Cooksley H, Chokshi S, Williams RO, et al
    Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:303.
    PubMed     Text format     Abstract available


  59. COOLES FA, Anderson AE, Drayton T, Harry RA, et al
    Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies.
    Arthritis Res Ther. 2016;18:302.
    PubMed     Text format     Abstract available


  60. PECANI A, Alessandri C, Spinelli FR, Priori R, et al
    Erratum to: Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases.
    Arthritis Res Ther. 2016;18:299.
    PubMed     Text format     Abstract available


  61. MCWILLIAMS DF, Ferguson E, Young A, Kiely PD, et al
    Discordant inflammation and pain in early and established rheumatoid arthritis: Latent Class Analysis of Early Rheumatoid Arthritis Network and British Society for Rheumatology Biologics Register data.
    Arthritis Res Ther. 2016;18:295.
    PubMed     Text format     Abstract available


  62. SELLAM J, Riviere E, Courties A, Rouzaire PO, et al
    Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:294.
    PubMed     Text format     Abstract available


  63. BERNELOT MOENS SJ, van der Valk FM, Strang AC, Kroon J, et al
    Erratum to: Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study.
    Arthritis Res Ther. 2016;18:298.
    PubMed     Text format    


  64. DE JONG TD, Blits M, de Ridder S, Vosslamber S, et al
    Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters.
    Arthritis Res Ther. 2016;18:290.
    PubMed     Text format     Abstract available


  65. JIANG X, Askling J, Saevarsdottir S, Padyukov L, et al
    A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy - results from a Swedish cohort study.
    Arthritis Res Ther. 2016;18:288.
    PubMed     Text format     Abstract available


  66. JOSHUA V, Schobers L, Titcombe PJ, Israelsson L, et al
    Antibody responses to de novo identified citrullinated fibrinogen peptides in rheumatoid arthritis and visualization of the corresponding B cells.
    Arthritis Res Ther. 2016;18:284.
    PubMed     Text format     Abstract available


  67. HARROLD LR, Reed GW, Solomon DH, Curtis JR, et al
    Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
    Arthritis Res Ther. 2016;18:280.
    PubMed     Text format     Abstract available


  68. VAN WESEMAEL TJ, Ajeganova S, Humphreys J, Terao C, et al
    Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study.
    Arthritis Res Ther. 2016;18:285.
    PubMed     Text format     Abstract available


  69. HUMPHREYS J, Hyrich K, Symmons D
    What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?
    Arthritis Res Ther. 2016;18:282.
    PubMed     Text format     Abstract available


  70. WITHROW J, Murphy C, Liu Y, Hunter M, et al
    Extracellular vesicles in the pathogenesis of rheumatoid arthritis and osteoarthritis.
    Arthritis Res Ther. 2016;18:286.
    PubMed     Text format     Abstract available


    November 2016
  71. LJUNG L, Rantapaa-Dahlqvist S
    Abdominal obesity, gender and the risk of rheumatoid arthritis - a nested case-control study.
    Arthritis Res Ther. 2016;18:277.
    PubMed     Text format     Abstract available


  72. BONDT A, Wuhrer M, Kuijper TM, Hazes JM, et al
    Fab glycosylation of immunoglobulin G does not associate with improvement of rheumatoid arthritis during pregnancy.
    Arthritis Res Ther. 2016;18:274.
    PubMed     Text format     Abstract available


  73. PECANI A, Alessandri C, Spinelli FR, Priori R, et al
    Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases.
    Arthritis Res Ther. 2016;18:276.
    PubMed     Text format     Abstract available


  74. BRUIJNEN S, Tsang-A-Sjoe M, Raterman H, Ramwadhdoebe T, et al
    B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.
    Arthritis Res Ther. 2016;18:266.
    PubMed     Text format     Abstract available


  75. HERNANDEZ-CRUZ B, Marquez-Saavedra E, Caliz-Caliz R, Navarro-Sarabia F, et al
    Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic di
    Arthritis Res Ther. 2016;18:259.
    PubMed     Text format     Abstract available


  76. VERHOEVEN F, Prati C, Maguin-Gate K, Wendling D, et al
    Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:258.
    PubMed     Text format     Abstract available


  77. JOHANSSON L, Sherina N, Kharlamova N, Potempa B, et al
    Erratum to: Concentration of antibodies against Porphyromonas gingivalisis increased before the onset of symptoms of rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:257.
    PubMed     Text format    


    October 2016
  78. NIKIPHOROU E, Radner H, Chatzidionysiou K, Desthieux C, et al
    Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature.
    Arthritis Res Ther. 2016;18:251.
    PubMed     Text format     Abstract available


  79. LAVIELLE M, Mulleman D, Goupille P, Bahuaud C, et al
    Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.
    Arthritis Res Ther. 2016;18:253.
    PubMed     Text format     Abstract available


  80. NAVARRO-MILLAN I, Darrah E, Westfall AO, Mikuls TR, et al
    Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.
    Arthritis Res Ther. 2016;18:241.
    PubMed     Text format     Abstract available


  81. MANZO A, Benaglio F, Vitolo B, Bortolotto C, et al
    Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors.
    Arthritis Res Ther. 2016;18:242.
    PubMed     Text format     Abstract available


  82. MANGNUS L, Nieuwenhuis WP, van Steenbergen HW, Huizinga TW, et al
    Body mass index and extent of MRI-detected inflammation: opposite effects in rheumatoid arthritis versus other arthritides and asymptomatic persons.
    Arthritis Res Ther. 2016;18:245.
    PubMed     Text format     Abstract available


  83. TURUNEN S, Huhtakangas J, Nousiainen T, Valkealahti M, et al
    Rheumatoid arthritis antigens homocitrulline and citrulline are generated by local myeloperoxidase and peptidyl arginine deiminases 2, 3 and 4 in rheumatoid nodule and synovial tissue.
    Arthritis Res Ther. 2016;18:239.
    PubMed     Text format     Abstract available


  84. VORDENBAUMEN S, Lueking A, Budde P, Zucht HD, et al
    Sequential high-content profiling of the IgG-autoantibody repertoire reveals novel antigens in rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:235.
    PubMed     Text format     Abstract available


  85. BURTEA C, Laurent S, Sanli T, Fanfone D, et al
    Screening for peptides targeted to IL-7Ralpha for molecular imaging of rheumatoid arthritis synovium.
    Arthritis Res Ther. 2016;18:230.
    PubMed     Text format     Abstract available


  86. HATTERER E, Shang L, Simonet P, Herren S, et al
    A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease.
    Arthritis Res Ther. 2016;18:224.
    PubMed     Text format     Abstract available


  87. BUGATTI S, Bogliolo L, Vitolo B, Manzo A, et al
    Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:226.
    PubMed     Text format     Abstract available


  88. ZHANG Y, Xu YZ, Sun N, Liu JH, et al
    Long noncoding RNA expression profile in fibroblast-like synoviocytes from patients with rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:227.
    PubMed     Text format     Abstract available


  89. BOYAPATI A, Msihid J, Fiore S, van Adelsberg J, et al
    Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.
    Arthritis Res Ther. 2016;18:225.
    PubMed     Text format     Abstract available


  90. TORICES S, Julia A, Munoz P, Varela I, et al
    A functional variant of TLR10 modifies the activity of NFkB and may help predict a worse prognosis in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:221.
    PubMed     Text format     Abstract available


    April 2016
  91. HARROLD LR, Reed GW, Kremer JM, Curtis JR, et al
    Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations.
    Arthritis Res Ther. 2016;18:94.
    PubMed     Text format     Abstract available


  92. HAN BK, Kuzin I, Gaughan JP, Olsen NJ, et al
    Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
    Arthritis Res Ther. 2016;18:93.
    PubMed     Text format     Abstract available


  93. PARK JK, Byun JY, Park JA, Kim YY, et al
    HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:91.
    PubMed     Text format     Abstract available


  94. OMETTO F, Raffeiner B, Bernardi L, Bostsios C, et al
    Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-month observational study.
    Arthritis Res Ther. 2016;18:89.
    PubMed     Text format     Abstract available


  95. MUELLER RB, Gengenbacher M, Richter S, Dudler J, et al
    Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).
    Arthritis Res Ther. 2016;18:88.
    PubMed     Text format     Abstract available


  96. EDHAYAN G, Ohara RA, Stinson WA, Amin MA, et al
    Inflammatory properties of inhibitor of DNA binding 1 secreted by synovial fibroblasts in rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:87.
    PubMed     Text format     Abstract available


  97. BARTLETT DB, Connelly MA, AbouAssi H, Bateman LA, et al
    A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls.
    Arthritis Res Ther. 2016;18:86.
    PubMed     Text format     Abstract available


  98. YOO DH, Racewicz A, Brzezicki J, Yatsyshyn R, et al
    A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
    Arthritis Res Ther. 2016;18:82.
    PubMed     Text format     Abstract available


  99. VAN BEERS-TAS MH, Marotta A, Boers M, Maksymowych WP, et al
    A prospective cohort study of 14-3-3eta in ACPA and/or RF-positive patients with arthralgia.
    Arthritis Res Ther. 2016;18:76.
    PubMed     Text format     Abstract available


  100. GONZALO-GIL E, Perez-Lorenzo MJ, Galindo M, Diaz de la Guardia R, et al
    Human embryonic stem cell-derived mesenchymal stromal cells ameliorate collagen-induced arthritis by inducing host-derived indoleamine 2,3 dioxygenase.
    Arthritis Res Ther. 2016;18:77.
    PubMed     Text format     Abstract available


    March 2016
  101. GARCIA S, Hartkamp LM, Malvar-Fernandez B, van Es IE, et al
    Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:75.
    PubMed     Text format     Abstract available


  102. KARABIS A, Nikolakopoulos S, Pandhi S, Papadimitropoulou K, et al
    High correlation of VAS pain scores after 2 and 6 weeks of treatment with VAS pain scores at 12 weeks in randomised controlled trials in rheumatoid arthritis and osteoarthritis: meta-analysis and implications.
    Arthritis Res Ther. 2016;18:73.
    PubMed     Text format     Abstract available


  103. RAMIREZ J, Celis R, Usategui A, Ruiz-Esquide V, et al
    Immunopathologic characterization of ultrasound-defined synovitis in rheumatoid arthritis patients in clinical remission.
    Arthritis Res Ther. 2016;18:74.
    PubMed     Text format     Abstract available


  104. TRUCHETET ME, Poursac N, Barnetche T, Shipley E, et al
    Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry.
    Arthritis Res Ther. 2016;18:72.
    PubMed     Text format     Abstract available


  105. TROPEA J, Brand CA, Bohensky M, Van Doornum S, et al
    Myocardial infarction and mortality following joint surgery in patients with rheumatoid arthritis: a retrospective cohort study.
    Arthritis Res Ther. 2016;18:69.
    PubMed     Text format     Abstract available


  106. OTA Y, Niiro H, Ota S, Ueki N, et al
    Generation mechanism of RANKL(+) effector memory B cells: relevance to the pathogenesis of rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:67.
    PubMed     Text format     Abstract available


  107. LIANG Q, Ju Y, Chen Y, Wang W, et al
    Lymphatic endothelial cells efferent to inflamed joints produce iNOS and inhibit lymphatic vessel contraction and drainage in TNF-induced arthritis in mice.
    Arthritis Res Ther. 2016;18:62.
    PubMed     Text format     Abstract available


  108. STEUNEBRINK LM, Versteeg GA, Vonkeman HE, Ten Klooster PM, et al
    Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry.
    Arthritis Res Ther. 2016;18:60.
    PubMed     Text format     Abstract available


    February 2016
  109. SHIOZAWA K, Yamane T, Murata M, Yoshihara R, et al
    MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.
    Arthritis Res Ther. 2016;18:55.
    PubMed     Text format     Abstract available


    January 2016
  110. HEIMANS L, Akdemir G, Boer KV, Goekoop-Ruiterman YP, et al
    Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study).
    Arthritis Res Ther. 2016;18:23.
    PubMed     Text format     Abstract available


  111. BAY-JENSEN AC, Platt A, Siebuhr AS, Christiansen C, et al
    Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study.
    Arthritis Res Ther. 2016;18:13.
    PubMed     Text format     Abstract available


  112. COSTA S, Schutz S, Cornec D, Uguen A, et al
    B-cell and T-cell quantification in minor salivary glands in primary Sjogren's syndrome: development and validation of a pixel-based digital procedure.
    Arthritis Res Ther. 2016;18:21.
    PubMed     Text format     Abstract available


  113. LACERTE P, Brunet A, Egarnes B, Duchene B, et al
    Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists.
    Arthritis Res Ther. 2016;18:10.
    PubMed     Text format     Abstract available


  114. THAM M, Schlor GR, Yerly D, Mueller C, et al
    Reduced pro-inflammatory profile of gammadeltaT cells in pregnant patients with rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:26.
    PubMed     Text format     Abstract available


  115. TER WEE MM, van Tuyl LH, Blomjous BS, Lems WF, et al
    Content validity of the Dutch Rheumatoid Arthritis Impact of Disease (RAID) score: results of focus group discussions in established rheumatoid arthritis patients and comparison with the International Classification of Functioning, Disability and Heal
    Arthritis Res Ther. 2016;18:22.
    PubMed     Text format     Abstract available


  116. DE GROOF A, Ducreux J, Humby F, Nzeusseu Toukap A, et al
    Higher expression of TNFalpha-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy.
    Arthritis Res Ther. 2016;18:19.
    PubMed     Text format     Abstract available


  117. JUAREZ M, McGettrick HM, Scheel-Toellner D, Yeo L, et al
    DKK1 expression by synovial fibroblasts in very early rheumatoid arthritis associates with lymphocyte adhesion in an in vitro flow co-culture system.
    Arthritis Res Ther. 2016;18:14.
    PubMed     Text format     Abstract available


  118. POZSGAY J, Babos F, Uray K, Magyar A, et al
    In vitro eradication of citrullinated protein specific B-lymphocytes of rheumatoid arthritis patients by targeted bifunctional nanoparticles.
    Arthritis Res Ther. 2016;18:15.
    PubMed     Text format     Abstract available


  119. HONNE K, Hallgrimsdottir I, Wu C, Sebro R, et al
    A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:12.
    PubMed     Text format     Abstract available


  120. YAMANAKA H, Tanaka Y, Takeuchi T, Sugiyama N, et al
    Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
    Arthritis Res Ther. 2016;18:34.
    PubMed     Text format     Abstract available


  121. INNALA L, Sjoberg C, Moller B, Ljung L, et al
    Co-morbidity in patients with early rheumatoid arthritis - inflammation matters.
    Arthritis Res Ther. 2016;18:33.
    PubMed     Text format     Abstract available


  122. ALIVERNINI S, Peluso G, Fedele AL, Tolusso B, et al
    Tapering and discontinuation of TNF-alpha blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission.
    Arthritis Res Ther. 2016;18:39.
    PubMed     Text format     Abstract available


  123. CARRIER N, Marotta A, de Brum-Fernandes AJ, Liang P, et al
    Serum levels of 14-3-3eta protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis.
    Arthritis Res Ther. 2016;18:37.
    PubMed     Text format     Abstract available


  124. BRINK M, Hansson M, Mathsson-Alm L, Wijayatunga P, et al
    Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:43.
    PubMed     Text format     Abstract available


  125. CHATZIDIONYSIOU K, Lie E, Nasonov E, Lukina G, et al
    Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.
    Arthritis Res Ther. 2016;18:50.
    PubMed     Text format     Abstract available


  126. GULFE A, Wallman JK, Kristensen LE
    EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
    Arthritis Res Ther. 2016;18:51.
    PubMed     Text format     Abstract available


  127. SIMON TA, Thompson A, Gandhi KK, Hochberg MC, et al
    Erratum to: Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis.
    Arthritis Res Ther. 2016;18:100.
    PubMed     Text format    


  128. REED E, Jiang X, Kharlamova N, Ytterberg AJ, et al
    Antibodies to carbamylated alpha-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies.
    Arthritis Res Ther. 2016;18:96.
    PubMed     Text format     Abstract available


  129. WU CY, Chen DY, Shen JL, Ho HJ, et al
    Erratum to: The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.
    Arthritis Res Ther. 2016;18:110.
    PubMed     Text format    


  130. HWANG YG, Balasubramani GK, Metes ID, Levesque MC, et al
    Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker.
    Arthritis Res Ther. 2016;18:108.
    PubMed     Text format     Abstract available


  131. OMETTO F, Raffeiner B, Bernardi L, Botsios C, et al
    Erratum to: Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-month observational study.
    Arthritis Res Ther. 2016;18:120.
    PubMed     Text format    


  132. ROOS K, Martinsson K, Ziegelasch M, Sommarin Y, et al
    Circulating secretory IgA antibodies against cyclic citrullinated peptides in early rheumatoid arthritis associate with inflammatory activity and smoking.
    Arthritis Res Ther. 2016;18:119.
    PubMed     Text format     Abstract available


  133. TAKESHITA M, Kuno A, Suzuki K, Matsuda A, et al
    Alteration of matrix metalloproteinase-3 O-glycan structure as a biomarker for disease activity of rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:112.
    PubMed     Text format     Abstract available


  134. BERNELOT MOENS SJ, van der Valk FM, Strang AC, Kroon J, et al
    Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study.
    Arthritis Res Ther. 2016;18:115.
    PubMed     Text format     Abstract available


  135. SMOLEN JS, Strand V, Koenig AS, Szumski A, et al
    Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity.
    Arthritis Res Ther. 2016;18:114.
    PubMed     Text format     Abstract available


  136. DE WINTER LM, Geusens P, Lenaerts J, Vanhoof J, et al
    The isotype repertoire of antibodies against novel UH-RA peptides in rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:130.
    PubMed     Text format     Abstract available


  137. JOHANSSON L, Pratesi F, Brink M, Arlestig L, et al
    Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:127.
    PubMed     Text format     Abstract available


  138. HRUSKOVA V, Jandova R, Vernerova L, Mann H, et al
    MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:124.
    PubMed     Text format     Abstract available


  139. FERRACCIOLI G, Tolusso B, Gremese E
    Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
    Arthritis Res Ther. 2016;18:126.
    PubMed     Text format     Abstract available


  140. BUISMAN LR, Luime JJ, Oppe M, Hazes JM, et al
    A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:135.
    PubMed     Text format     Abstract available


  141. GENOVESE MC, van Vollenhoven RF, Wilkinson B, Wang L, et al
    Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:145.
    PubMed     Text format     Abstract available


  142. CHATZIDIONYSIOU K, Lie E, Nasonov E, Lukina G, et al
    Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.
    Arthritis Res Ther. 2016;18:144.
    PubMed     Text format    


  143. MIAN AN, Ibrahim F, Scott DL, Galloway J, et al
    Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?
    Arthritis Res Ther. 2016;18:142.
    PubMed     Text format     Abstract available


  144. ALBRECHT K, Richter A, Callhoff J, Huscher D, et al
    Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases.
    Arthritis Res Ther. 2016;18:149.
    PubMed     Text format     Abstract available


  145. INCIARTE-MUNDO J, Ramirez J, Hernandez MV, Ruiz-Esquide V, et al
    Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Arthritis Res Ther. 2016;18:160.
    PubMed     Text format     Abstract available


  146. NAKAMURA S, Suzuki K, Iijima H, Hata Y, et al
    Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study.
    Arthritis Res Ther. 2016;18:159.
    PubMed     Text format     Abstract available


  147. MUCKE J, Hoyer A, Brinks R, Bleck E, et al
    Inhomogeneity of immune cell composition in the synovial sublining: linear mixed modelling indicates differences in distribution and spatial decline of CD68+ macrophages in osteoarthritis and rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:170.
    PubMed     Text format     Abstract available


  148. MEISSNER Y, Zink A, Kekow J, Rockwitz K, et al
    Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:183.
    PubMed     Text format     Abstract available


  149. STRADNER MH, Dejaco C, Brickmann K, Graninger WB, et al
    A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study.
    Arthritis Res Ther. 2016;18:190.
    PubMed     Text format     Abstract available


  150. CUPPEN BV, Rossato M, Fritsch-Stork RD, Concepcion AN, et al
    Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
    Arthritis Res Ther. 2016;18:189.
    PubMed     Text format     Abstract available


  151. JOHANSSON L, Sherina N, Kharlamova N, Potempa B, et al
    Concentration of antibodies against Porphyromonas gingivalis is increased before the onset of symptoms of rheumatoid arthritis.
    Arthritis Res Ther. 2016;18:201.
    PubMed     Text format     Abstract available


  152. STRAND V, Kosinski M, Chen CI, Joseph G, et al
    Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Arthritis Res Ther. 2016;18:198.
    PubMed     Text format     Abstract available


  153. LANDEWE RB, Connell CA, Bradley JD, Wilkinson B, et al
    Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials.
    Arthritis Res Ther. 2016;18:212.
    PubMed     Text format     Abstract available


  154. TEITSMA XM, Marijnissen AK, Bijlsma JW, Lafeber FP, et al
    Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials.
    Arthritis Res Ther. 2016;18:211.
    PubMed     Text format     Abstract available


  155. ANDREASSON K, Ohlsson B, Mandl T
    Elevated levels of faecal calprotectin in primary Sjogren's syndrome is common and associated with concomitant organic gastrointestinal disease.
    Arthritis Res Ther. 2016;18:9.
    PubMed     Text format     Abstract available


    January 2015
  156. SIMS NA, Romas E
    Is RANKL inhibition both anti-resorptive and anabolic in rheumatoid arthritis?
    Arthritis Res Ther. 2015;17:328.
    PubMed     Text format     Abstract available


  157. BARBER CE, Patel JN, Woodhouse L, Smith C, et al
    Development of key performance indicators to evaluate centralized intake for patients with osteoarthritis and rheumatoid arthritis.
    Arthritis Res Ther. 2015;17:322.
    PubMed     Text format     Abstract available


  158. WEINBLATT ME, Fleischmann R, van Vollenhoven RF, Emery P, et al
    Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Arthritis Res Ther. 2015;17:325.
    PubMed     Text format     Abstract available


  159. LOWIN T, Apitz M, Anders S, Straub RH, et al
    Anti-inflammatory effects of N-acylethanolamines in rheumatoid arthritis synovial cells are mediated by TRPV1 and TRPA1 in a COX-2 dependent manner.
    Arthritis Res Ther. 2015;17:321.
    PubMed     Text format     Abstract available


  160. SHI J, van Steenbergen HW, van Nies JA, Levarht EW, et al
    The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis.
    Arthritis Res Ther. 2015;17:339.
    PubMed     Text format     Abstract available


  161. GOMEZ-BANUELOS E, Navarro-Hernandez RE, Corona-Meraz F, Madrigal-Ruiz PM, et al
    Serum leptin and serum leptin/serum leptin receptor ratio imbalance in obese rheumatoid arthritis patients positive for anti-cyclic citrullinated peptide antibodies.
    Arthritis Res Ther. 2015;17:335.
    PubMed     Text format     Abstract available


  162. BINGHAM CO 3RD, Winthrop KL, Yang L, Lee C, et al
    BAFF inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2015;17:347.
    PubMed     Text format    


  163. PAULISSEN SM, van Hamburg JP, Davelaar N, Vroman H, et al
    CCR6(+) Th cell populations distinguish ACPA positive from ACPA negative rheumatoid arthritis.
    Arthritis Res Ther. 2015;17:344.
    PubMed     Text format     Abstract available


  164. POPE J, Bingham CO 3rd, Fleischmann RM, Dougados M, et al
    Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.
    Arthritis Res Ther. 2015;17:343.
    PubMed     Text format     Abstract available


  165. STRAND V, Ahadieh S, French J, Geier J, et al
    Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
    Arthritis Res Ther. 2015;17:362.
    PubMed     Text format     Abstract available


  166. SMITH SL, Eyre S, Yarwood A, Hyrich K, et al
    Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples.
    Arthritis Res Ther. 2015;17:359.
    PubMed     Text format     Abstract available


  167. PIKWER M, Orellana C, Kallberg H, Pikwer A, et al
    Parity influences the severity of ACPA-negative early rheumatoid arthritis: a cohort study based on the Swedish EIRA material.
    Arthritis Res Ther. 2015;17:358.
    PubMed     Text format     Abstract available


  168. MIGITA K, Akeda Y, Akazawa M, Tohma S, et al
    Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients.
    Arthritis Res Ther. 2015;17:357.
    PubMed     Text format     Abstract available


  169. SUURMOND J, Dorjee AL, Boon MR, Knol EF, et al
    Retraction Note: Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium.
    Arthritis Res Ther. 2015;17:354.
    PubMed     Text format    


  170. GOLINSKI ML, Vandhuick T, Derambure C, Freret M, et al
    Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFalpha inhibitors.
    Arthritis Res Ther. 2015;17:382.
    PubMed     Text format     Abstract available


  171. BLACK RJ, Joseph RM, Brown B, Movahedi M, et al
    Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study.
    Arthritis Res Ther. 2015;17:375.
    PubMed     Text format     Abstract available


  172. SHIN JH, Lee Y, Kim SG, Choi BY, et al
    The beneficial effects of Tai Chi exercise on endothelial function and arterial stiffness in elderly women with rheumatoid arthritis.
    Arthritis Res Ther. 2015;17:380.
    PubMed     Text format     Abstract available


  173. XU K, Cai YS, Lu SM, Li XL, et al
    Autophagy induction contributes to the resistance to methotrexate treatment in rheumatoid arthritis fibroblast-like synovial cells through high mobility group box chromosomal protein 1.
    Arthritis Res Ther. 2015;17:374.
    PubMed     Text format     Abstract available


  174. NAGEL J, Geborek P, Saxne T, Jonsson G, et al
    The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients.
    Arthritis Res Ther. 2015;17:124.
    PubMed     Text format     Abstract available


  175. BIAN F, Barbosa FL, Corrales RM, Pelegrino FS, et al
    Altered balance of interleukin-13/interferon-gamma contributes to lacrimal gland destruction and secretory dysfunction in CD25 knockout model of Sjogren's syndrome.
    Arthritis Res Ther. 2015;17:53.
    PubMed     Text format     Abstract available


  176. BALDINI C, Luciano N, Tarantini G, Pascale R, et al
    Salivary gland ultrasonography: a highly specific tool for the early diagnosis of primary Sjogren's syndrome.
    Arthritis Res Ther. 2015;17:146.
    PubMed     Text format     Abstract available


  177. NAIR N, Mei HE, Chen SY, Hale M, et al
    Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.
    Arthritis Res Ther. 2015;17:127.
    PubMed     Text format     Abstract available


  178. MULLEN LM, Chamberlain G, Sacre S
    Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease.
    Arthritis Res Ther. 2015;17:122.
    PubMed     Text format     Abstract available


  179. NANUS DE, Filer AD, Yeo L, Scheel-Toellner D, et al
    Differential glucocorticoid metabolism in patients with persistent versus resolving inflammatory arthritis.
    Arthritis Res Ther. 2015;17:121.
    PubMed     Text format     Abstract available


  180. PISETSKY DS
    Rheumatoid vasculitis: going, going, but not yet gone.
    Arthritis Res Ther. 2015;17:116.
    PubMed     Text format    


  181. TERAO C, Ohmura K, Kochi Y, Ikari K, et al
    Anti-citrullinated peptide/protein antibody (ACPA)-negative RA shares a large proportion of susceptibility loci with ACPA-positive RA: a meta-analysis of genome-wide association study in a Japanese population.
    Arthritis Res Ther. 2015;17:104.
    PubMed     Text format     Abstract available


  182. MCALLEN RM, Cook AD, Khiew HW, Martelli D, et al
    The interface between cholinergic pathways and the immune system and its relevance to arthritis.
    Arthritis Res Ther. 2015;17:87.
    PubMed     Text format     Abstract available


  183. GRAVANI F, Papadaki I, Antypa E, Nezos A, et al
    Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations.
    Arthritis Res Ther. 2015;17:99.
    PubMed     Text format     Abstract available


  184. WALDELE S, Koers-Wunrau C, Beckmann D, Korb-Pap A, et al
    Deficiency of fibroblast activation protein alpha ameliorates cartilage destruction in inflammatory destructive arthritis.
    Arthritis Res Ther. 2015;17:12.
    PubMed     Text format     Abstract available


  185. MANIVEL VA, Sohrabian A, Wick MC, Mullazehi M, et al
    Anti-type II collagen immune complex-induced granulocyte reactivity is associated with joint erosions in RA patients with anti-collagen antibodies.
    Arthritis Res Ther. 2015;17:8.
    PubMed     Text format     Abstract available


  186. KARPUS ON, Kiener HP, Niederreiter B, Yilmaz-Elis AS, et al
    CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis.
    Arthritis Res Ther. 2015;17:6.
    PubMed     Text format     Abstract available


  187. YANG Z, Matteson EL, Goronzy JJ, Weyand CM, et al
    T-cell metabolism in autoimmune disease.
    Arthritis Res Ther. 2015;17:29.
    PubMed     Text format     Abstract available


  188. VERBRUGGE SE, Scheper RJ, Lems WF, de Gruijl TD, et al
    Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
    Arthritis Res Ther. 2015;17:17.
    PubMed     Text format     Abstract available


  189. ORNBJERG LM, Ostergaard M, Jensen T, Hyldstrup L, et al
    Establishment of age- and sex-adjusted reference data for hand bone mass and investigation of hand bone loss in patients with rheumatoid arthritis treated in clinical practice: an observational study from the DANBIO registry and the Copenhagen Osteoar
    Arthritis Res Ther. 2016;18:53.
    PubMed     Text format     Abstract available


  190. KRAGSTRUP TW, Greisen SR, Nielsen MA, Rhodes C, et al
    The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression.
    Arthritis Res Ther. 2016;18:61.
    PubMed     Text format     Abstract available


  191. CANETE JD, Celis R, Yeremenko N, Sanmarti R, et al
    Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis.
    Arthritis Res Ther. 2015;17:173.
    PubMed     Text format     Abstract available


  192. MUSCHTER D, Gottl C, Vogel M, Grifka J, et al
    Reactivity of rat bone marrow-derived macrophages to neurotransmitter stimulation in the context of collagen II-induced arthritis.
    Arthritis Res Ther. 2015;17:169.
    PubMed     Text format     Abstract available


  193. DHIR V, Sandhu A, Kaur J, Pinto B, et al
    Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study).
    Arthritis Res Ther. 2015;17:156.
    PubMed     Text format     Abstract available


  194. MC ARDLE A, Flatley B, Pennington SR, FitzGerald O, et al
    Early biomarkers of joint damage in rheumatoid and psoriatic arthritis.
    Arthritis Res Ther. 2015;17:141.
    PubMed     Text format     Abstract available


  195. NOSS EH, Watts GF, Zocco D, Keller TL, et al
    Evidence for cadherin-11 cleavage in the synovium and partial characterization of its mechanism.
    Arthritis Res Ther. 2015;17:126.
    PubMed     Text format     Abstract available


  196. VAN NIES JA, Alves C, Radix-Bloemen AL, Gaujoux-Viala C, et al
    Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH.
    Arthritis Res Ther. 2015;17:108.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: